Autopsy report · NCT02656615

Abiraterone-Rechallenge Study for CRPC Patients

“Lack of Patient accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 1 month before it stopped.
• 4 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Aurelius Omlin

Sponsor type

University, hospital or other

Conditions

Prostate Cancer

Interventions

abiraterone acetate

Participants

4

Sites

3

Countries

Switzerland

Trials that died the same way

• Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
  “Lack of patient accruals.” (94% match in meaning)
• Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma
  “Inadequate patient accrual” (93% match in meaning)
• A Study on the Angioarchitecture of Hepatocellular Carcinoma
  “Poor patient accrual” (89% match in meaning)
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
  “lack of patient population - slow accrual” (83% match in meaning)
• SOX as Salvage Treatment in Nasopharyngeal Carcinoma
  “poor accrual of eligible patients” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.